1224288-92-9

Usage

Uses

Used in Pharmaceutical Industry:
5-Chloropyrazolo[1,5-a]pyrimidine-3-carbonitrile is used as a building block for the synthesis of various organic compounds, contributing to the development of new pharmaceuticals and agrochemicals. Its unique structure and potential biological activities make it a valuable intermediate in the production of drugs with diverse therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-Chloropyrazolo[1,5-a]pyrimidine-3-carbonitrile is utilized as a reagent in organic synthesis, facilitating the creation of new drugs with potential antitumor and antimicrobial properties. Its presence in the molecular structure of these compounds can enhance their therapeutic efficacy and selectivity, leading to improved treatment options for various diseases.
Used in Organic Synthesis:
As an important intermediate in organic synthesis, 5-Chloropyrazolo[1,5-a]pyrimidine-3-carbonitrile is employed in the preparation of a wide range of chemical compounds. Its versatility in forming various functional groups and its compatibility with different synthetic routes make it a valuable component in the development of novel organic molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.

Upstream product

• 1224288-95-2 5-oxo-4,5-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile 
• 1224288-95-2 5-hydroxypyrazolo[1,5-a]pyrimidine-3-carbonitrile 
• 1621718-74-8 (E)-5-chloropyrazolo[1,5-a]pyrimidine-3-carbaldehyde oxime 
• 1256162-94-3 5-chloropyrazolo[1,5-a]pyrimidine-3-carbaldehyde 
• 29274-24-6 5-chloropyrazolo[1,5-a]pyrimidine 

Downstream Products

• 478081-98-0 N-(3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl)-N-ethylacetamide 
• 1224289-06-8 5-(3-aminophenyl)pyrazolo[1,5-a]pyrimidin-3-carbonitrile 
• 1224289-04-6 5-(3-nitrophenyl)pyrazolo[1,5-a]pyrimidin-3-carbonitrile 
• 1224289-08-0 N-(3-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl)acetamide 
• 1260846-28-3 (R)-5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile 
• 1621718-29-3 N-(5-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO NTRK

This invention relates to inhibitors of NTRK comprising a pyrazolo[1,5-4]pyrimidine-3-carbonitrile structure. They are active against wild-type NTRK and its resistant mutants.

FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS

The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases. In some compounds of Formula I, Q is —CH═CR3C(O)NR4R5, —C≡CC(O)NR4R5, or

HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE

The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Synthetic studies connected with the preparation of N-[3-(3- cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethylacetamide, a zaleplon regioisomer

N-[3-(3-Cyanopyrazolo[1,5-a]pyrimidin-5-yl)phenyl]-N-ethyl-acetamide, a principal impurity of zaleplon, is prepared by Suzuki-Miyaura cross coupling reaction of the corresponding boronic acid and/or boronates with 5-chloropyrazolo[1,5-a]pyrimidin-3-carbonitrile (7). Various methods of preparation of both components are described, as well as approaches based on the final modification of the 5-(3-aminophenyl)-pyrazolo[1,5-a]pyrimidine-3- carbonitrile moiety prepared by Suzuki-Miyaura cross coupling. All the prepared compounds were unambiguouesly identified by NMR techniques. Spectral characteristics (IR, UV, MS) of these compounds are also given.